Print this page    •   Back to Web version of article

Nevirapine Prolonged Release Once-Daily Formulation Available in the UK

January/February 2012

Following the approval in Europe last year of a prolonged release (PR) formulation of nevirapine (called extended release/XR in the US), this 400 mg once-daily tablet is now available in the UK.

The lead in dose of 200 mg once daily (using the original formulation) is still required, with the same caution not to increase to the 400 mg daily dose if the patient shows rash at the end of these 14 days.

The daily price of nevirapine PR has been price matched to the price of the 200 mg formulation.


Reference

  1. Boehringer press release: Viramune (nevirapine) prolonged-release once-daily formulation receives approval in the EU. (Septemebr 2011).

Links to external websites are current at time of posting but not maintained.




This article was provided by HIV i-Base. It is a part of the publication HIV Treatment Bulletin. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/65853/nevirapine-prolonged-release-once-daily-formulatio.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.